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Although originally conceived in the mid 
1970s as an alternative to transfection (Goff 
and Berg, 1976), the use of viral vectors as a 
tool for clinical gene therapy did not emerge 
until the 1980s. As Li and Ertl (2011) reca-
pitulate in their thought provoking per-
spective, viruses meet all the requirements 
needed for gene therapy. Evolving since 
life’s beginning, viruses have established 
the ability to efficiently infect and transfer 
their genomes in a wide variety of mam-
malian cell types. Likewise, and generally 
considered beneficial for survival, mam-
mals have equally evolved highly complex 
mechanisms to protect themselves against 
invading pathogens such as viral gene trans-
fer vectors. However, it is this protective 
immune response that often presents major 
obstacles for successful long-term therapy. 
Fortunately, the gene transfer community 
has been extensively studying the mecha-
nisms of immune responses against viral 
vectors and has started to develop strategies 
and protocols to block or circumvent such 
responses. In this Research Topic, the edi-
tors present a collection of mini-Reviews, 
in-depth Reviews, Perspective, and Primary 
research articles that highlight both the well 
established and emerging strategies cur-
rently being used in blocking the immune 
response to gene transfer with viral vectors.
Viral vectors such as adenovirus and 
adenovirus-associated virus (AAV) are 
superior tools for gene therapy due to their 
high efficiency of transduction into a variety 
of cells in vivo. Administration of viral vec-
tors often provokes the initiation of innate 
and antigen-specific adaptive immune 
responses against the virus and/or the 
therapeutic transgene products. Activation 
of these pathways elicits a flurry of anti-
viral and pro-inflammatory signals that can 
recruit effector lymphocytes, inhibit viral 
transduction, and encourage elimination 
of transduced cells over a period of time. 
Additionally, the de novo expression of a 
They also highlight strategies proposed 
to either mitigate or harness Ad-induced 
innate and adaptive immune responses for 
the improved and broadened development 
of advanced, Ad-based therapies.
Adenovirus-associated virus vectors 
have shown considerable promise as a 
gene delivery tool for clinical gene therapy 
applications. Unfortunately, the presence 
of pre-formed neutralizing antibodies 
directed against the AAV capsid in a large 
proportion of the human population due to 
widespread prior exposure to the wild-type 
virus has prevented AAV from reaching its 
full potential as a gene therapy vector. Bartel 
et al. (2011) provide an intriguing review 
that examines the use of capsid engineer-
ing as a means to evade pre-existing immu-
nity. The authors discuss the consequences 
of humoral anti-AAV immune responses 
and potential strategies to prevent them. 
Additionally, Arnett et al. (2011) discusses 
the influence that cross reactivity of pre-
existing antibodies has on gene therapy, 
including neonatal administration of viral 
vectors as a means to circumvent such anti-
body responses.
As a target tissue for gene therapy, mus-
cle is appealing because it is abundant, eas-
ily accessible, and procedures involving gene 
transfer to muscle are relatively safe and 
non-invasive (Hoffman et al., 2007). The 
mini-review by Wang et al. focuses on recent 
reports of immunity to AAV capsid proteins 
and transgene products in the context of 
gene delivery to muscles for treating both 
muscular dystrophies and other non-muscle 
diseases. They provide strategies of immune 
modulation and tolerance induction in order 
to prevent unwanted immune responses to 
the vector and/or the therapeutic gene prod-
uct (Wang et al., 2011). Additionally, the 
research article presented by the Boyer group, 
evaluates a treatment protocol designed to 
inhibit the deleterious immune activation 
during  muscle gene transfer. Their strategy 
wild-type protein may trigger an adaptive 
immune response in the form of neutral-
izing antibodies. Likewise, pre-existing 
immunity (immunological memory) to 
the gene transfer vector resulting from prior 
exposure to the virus often prevents efficient 
gene transfer. All of these scenarios pose 
serious hurdles for successful gene therapy.
The first review article of this special 
topic provides a comprehensive overview 
of the innate immune responses to AAV. 
The authors highlight and discuss recent 
discoveries regarding strategies to abro-
gate potentially detrimental signaling 
pathways (Rogers et al., 2011). Historically, 
the innate immune response to single-
stranded AAVs has been considered weak 
and transient when compared to the potent 
and prolonged response elicited by Ad vec-
tors, thus prompting many investigators 
to focus more on the adaptive immune 
response to AAV. In more recent years our 
understanding of the early innate mecha-
nisms of immune responses to viral vectors 
has greatly improved. The authors present 
an up-to-date analysis of the mechanisms 
surrounding the innate immune response 
to single-stranded and self-complimentary 
AAVs, including the role of the viral cap-
sid, the effects on target tissue, and the 
therapeutic potential of blocking innate 
responses.
An equally impressive review detailing 
the current understanding relative to Ad 
vector mediated induction of the innate and 
adaptive immune responses is presented by 
Aldhamen et al. (2011). Ad vectors possess 
several advantages, the most important of 
which is that they can be easily, and rou-
tinely produced to high titers, however 
they also rapidly activate innate immune 
responses as well as potent cellular and 
humoral adaptive immune responses. This 
review examines the impact these responses 
have on the safety and efficacy of Ad vector-
based therapies (Aldhamen et al., 2011). 
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induce the transgene-specific regulatory T 
cells (Goudy et al., 2011). Another method 
to modulate tolerance induction is via gene 
transfer to B-cells and such an approach is 
presented by Su et al. Here, the authors 
demonstrate that host IL-10 is critical for 
the tolerogenicity of B-cell based peptide–
IgG gene therapy (Su et al., 2011).
Overall, this Research Topic: “Approaches 
to Blocking the Immune Response to Gene 
Transfer with Viral Vectors” provides a well-
developed overview of the current thera-
peutic potentials of viral gene therapy. This 
collection of articles not only provides a 
dynamic review and analyses of the complex 
immune responses present in current gene 
therapy applications, but they also provide 
insight for the future direction of the field.
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is based on the administration of CTLA-4/
Ig in order to block the co-stimulatory sig-
nals required early during immune priming 
combined with gene transfer of PD-1 ligands 
to inhibit T cell functions at the tissue sites 
(Adriouch et al., 2011).
It has become evident that the manipula-
tion of various co-stimulatory pathways to 
regulate host immune responses is of thera-
peutic interest. Addressing this, Huang and 
Yang, offer a broad review of relevant T cell 
co-stimulatory pathways in the activation of 
both T and B-cells, and provide strategies for 
targeting these co-stimulatory pathways in 
gene therapy applications. Ultimately, they 
suggest that studies should focus on target-
ing multiple pathways including both the 
positive and negative co-stimulatory path-
ways (Huang and Yang, 2011). Using a mul-
tiple pathway approach in an animal model 
of hemophilia, the Herzog lab presents new 
findings that suggest that transient immune 
modulation using a cocktail of rapamycin, 
IL-10, and specific peptides could prevent 
or possibly reverse gene therapy-induced 
inhibitor formation (Nayak et al., 2011).
The success of in vivo gene therapy not 
only depends on the ability to control the 
immune response toward the input vector, 
but also to the therapeutic transgene. Using 
both vector-based and pharmacological 
approaches, various groups have explored 
various approaches to control the immune-
mediated clearance of transgene-expressing 
cells after viral delivery. One approach using 
micro-RNA transgene regulation to gener-
ate a tolerogenic response is reviewed by 
Goudy et al. They further speculate on 
possible mechanisms used by the liver to 
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